IP Library Granted Patent US 10,512,564
Granted Patent B2
US 10,512,564 · App. 15/654,020 · Granted Dec 24, 2019

Combination treatments

Inventor: Lesco L. Rogers (Raleigh, NC)
Assignee: Scion Neurostim, LLC
A61F7/12A61K31/00A61F2007/0005A61F2007/0075A61F2007/0093A61F2007/0096A61F2007/0261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,512,564
App. No.
15/654,020
Granted
Dec 24, 2019
Kind
B2
Abstract

A method of treating a subject in need thereof, is carried out by (a) administering said subject a therapeutic intervention (e.g., an active agent) in a treatment effective amount; and concurrently (b) administering said subject caloric vestibular stimulation in a treatment effective amount, said caloric vestibular stimulation administered so as to enhance the efficacy of said active agent. In some embodiments, the caloric vestibular stimulation is administered as an actively controlled time varying waveform.

Claims (13)

1. A method of treating a subject afflicted with Parkinson's disease and in need of treatment thereof, comprising:

(a) administering said subject an active agent in a treatment effective amount; and concurrently

(b) administering said subject caloric vestibular stimulation in a treatment effective amount, said caloric vestibular stimulation administered so as to enhance the efficacy of said active agent, wherein said caloric vestibular stimulation is administered as an actively controlled time varying waveform and the subject is afflicted with Parkinson's disease.

2. The method of claim 1 , wherein said active agent is administered orally.

3. The method of claim 1 , wherein said active agent is selected from the group consisting of: levodopa, carbidopa, amantadine, pramipexole, ropinirole, pergolide, cabergoline, apomorphine, bromocriptine, MAOB inhibitors, COMT inhibitors, alpha-2 inhibitors, anticholinergics, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists, and inhibitors of neuronal nitric oxide synthase, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

4. The method of claim 3 , wherein said active agent is a MAOB inhibitor selected from the group consisting of: selegine and rasagiline.

5. The method of claim 3 , wherein said active agent is a COMT inhibitor selected from the group consisting of: entacapone and tolcapone.

6. The method of claim 3 , wherein said active agent is an anticholinergic selected from the group consisting of: benztropine, biperiden, orphenadrine, procyclidine, and trihexyphenidyl.

7. The method of claim 1 , wherein said caloric vestibular stimulation is administered for a time sufficient to induce nystagmus over a period of at least five minutes.

8. The method of claim 1 , wherein said caloric vestibular stimulation comprises a first thermal waveform delivered to a first ear canal of the subject.

9. The method of claim 8 , wherein said caloric vestibular stimulation comprises a second thermal waveform delivered to a second ear canal of the subject.

10. The method of claim 9 , wherein the first and second thermal waveforms are different.

11. The method of claim 1 , wherein said active agent comprises a medication for treatment of Parkinson's disease, the symptoms of Parkinson's disease or a combination thereof.

Assignments (1)
CHANGE OF NAME Recorded Jul 21, 2023
From: SCION NEUROSTIM, LLC
To: SCION NEUROSTIM, INC.
Reel/Frame 064360/0875 →